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Abstract 
 
Response to biologic therapies in severe asthma is variable, patients being either 
non-responders, responders or super-responders. There is currently no explanation 
for this variation in response. If asthma specific inflammatory pathways are part of a 
wider network of pathogenic mechanisms (including systemic inflammation), then the 
state of this wider network could either help or hinder the effect of the biologic. 
People with severe asthma are often polysymptomatic with a variable frequency of 
non-respiratory symptoms. Application of existing network theory would predict that 
high systemic inflammation, measurable by the frequency of non-respiratory 
symptoms, should decrease the effectiveness of biologics, a prediction consistent 
with limited existing data. A detailed examination of the relationship between 
biologic response and the frequency or profile of non-respiratory symptom would 
provide a testable prediction of this hypothesis. The clinical presentation of super- 
responders is consistent with biologics sometimes having a positive effect on the 
pathology (level of dysregulation) in a network system. If that were the case, then 
network theory predicts the possibility of a short-term increase in non-respiratory 
symptoms prior to the improvement reported by super-responders. If biologics lead 
to less network dysregulation in some patients, then this raises the possibility of new 
applications for this therapy and of an improved response to biologics if lifestyle 
improvement is started prior to biologic therapy. 
 
 
 
Keywords: Severe asthma, responder, network, complexity, biologic therapy, 
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Biologic therapies target specific inflammatory pathways involved in the 
pathogenesis of asthma, and because they have a highly specific effect on the 
inflammatory pathways, they reduce the inflammation of asthma with comparatively 
few side effects. The global initiative for asthma (GINA) guidelines for severe and 
difficult to treat asthma [1] provide the following guidance: 
“If available and affordable consider an-add on Type 2 targeted biologic for patients 
with exacerbations and eosinophilic and/or allergic biomarkers despite taking high 
dose ICS-LABA with or without daily OCS” p 23. 
Countries follow this recommendation but the criteria for number of exacerbations 
and levels of biomarkers varies between countries because availability and 
affordability varies between countries. In practice, this means that the use of 
biologics differs between countries, but in all countries biologics are restricted to the 
more severe patients for reasons of cost and evidence. 
Patients who are eligible according to the GINA criteria show a variable response to 
biologics. Expert opinion recommends a traffic light system based on assigning 
patients to three groups, non-responders, responders, and super-responders [2]. 
The consensus from this group is that a number of clinical indicators should be used 
to allocate patients to one of these three response groups and that the assessment 
should be made by the clinician after four months. The group did not define a super- 
responder, but clinical experience shows that some patients report biologics to be life 
changing as their life-dominating asthma all but disappears. The majority of eligible 
patients respond well to biologic treatment. Two large studies report 82- 83% of 
patients are responders to omalizumab [3,4] and two small studies report 76-77% of 
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patients are responders to mepolizumab [5,6], though the criteria for responder 
versus non-responder differ between studies, reflecting the consensus statement 
that several indicators can be used [2]. 
There are limited explanations for the variable response to biologics. In those 
patients who meet the criteria for raised eosinophilic or allergic biomarkers, higher 
levels of baseline biomarkers are associated with better response to a biologic in 
some studies [7-9], but not in others [6,10], but this mechanism cannot explain the 
substantial variation in response between non-responders and super-responders 
observed in clinical practice. Greater severity, measured by recent past 
exacerbations also predict better outcome measured by exacerbations [9, 11] though 
this may be due to regression to the mean. Other baseline characteristics when used 
as predictors show more variable results. In one study, age, obesity, comorbidities, 
smoking habits, nasal polyps, and allergic poly-sensitization were associated with 
reduced response to omalizumab [12]. However, in another study obesity and 
cardiovascular disease were not found to predict response to omalizumab [4]. One 
study found that sex, body mass index, smoking history, allergies, and baseline level 
of eosinophils did not predict treatment response to mepolizumab [6] ], and genetic 
markers have failed to predict outcome to mepolizumab [13], but there is preliminary 
evidence that exhaled breath analysis can predict outcome to mepolizumab [14]. 
 
 
 
The current theoretical model for the action of biologics can be represented by a 
linear causal sequence of an inflammatory pathway, see Figure 1a. According to 
this model, differences in response can be explained only in terms of the specific 
inflammatory mechanism – and based on predictor studies, there is little evidence 
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that this is the case. The proposed theoretical model expands this sequence by 
proposing that the target molecule is part of a causal network of other inflammatory 
markers or substances that have reciprocal causal relations. It is the state of this 
causal network that then determines the response of the target molecule to biologics, 
see Figure 1. The hypothesis that several pathogenic mechanisms have a network 
architecture has been proposed elsewhere, as networks provide an explanation for 
otherwise difficult to explain symptomatology of functional disorders [15]. Networks 
are highly sensitive to the rate of change on the simultaneous causal relations that 
occur between the nodes of the network and have emergent properties that are best 
understood in terms of algorithms or programs [16]. If multiple pathogenic, symptom 
causing mechanisms were connected to form a network architecture, then this would 
enable the body to adapt in ways that are more complex than previously thought. 
That is, the body would have the adaptive capability exhibited by a machine with 
artificial intelligence [15]. The adaptive network theory suggests that the body’s 
ability to adapt produces better regulation under most circumstance, but there are 
circumstances where it can produce dysregulation [17], dysregulation that then has 
wide spread effects on numerous mechanisms of pathology. 
Severe asthma is often a polysymtomatic disease with numerous but variable non- 
respiratory symptoms, that include both psychological symptoms (e.g., fatigue, 
mental fog) as well as somatic symptoms (e.g., stomach pain, cold hands and feet) 
(18). Many of these non-respiratory symptoms are a feature of systemic 
inflammation, but they are also a feature of medically unexplained symptoms that 
can be explained by a network of multiple symptom causing mechanisms (15,17). It 
is therefore plausible that inflammatory pathways leading to asthma are also part of 
a wider network of pathogenic mechanisms that include systemic inflammation. The 
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systemic network wide inflammation, of which the target molecule is part, could lock 
the target molecule into an inflammatory state, thereby reducing the effectiveness of 
the biologic treatment that would otherwise reduce inflammation. Systemic 
inflammation is an indicator of poorly functioning network, i.e., network dysregulation, 
and is associated with a number of non-respiratory symptoms. As different target 
molecules and different inflammatory pathways are embedded in different ways in 
the overarching inflammatory network, the relationship between biologic and non- 
respiratory symptoms could be biologic-specific. 
The first prediction is that: 
 
More non-respiratory symptoms should predict worse response to a biologic. 
Different non-respiratory profiles may predict response to different biologics. 
There is some existing evidence for this prediction. Depression reduces the 
effectiveness of biologics in arthritis [19], and comorbidity decreases effectiveness of 
a biologic in asthma [12]. However, there has been no systematic, theoretically 
driven investigation of the hypothesis. 
If an inflammatory pathway forms part of a wider network, then any therapy will affect 
not only the inflammatory pathway but also the wider network. It is possible for this 
effect to be either positive or negative. Glucocorticoids have a wide-ranging effect on 
the immune system, suppressing most cytokines, including anti-inflammatory 
cytokines [20]. These wide-ranging effects are more likely to have a dysregulatory 
effect on a finely tuned network leading to gradual adaptation that is pathogenic. 
The finding that systemic steroids often have an initial energising effect on patients 
but have long-term widespread adverse consequences is consistent with network 
functionality. Immediate change to the state of the network caused by the steroid is 
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followed by gradual change to the activation rules (the causal connections between 
the nodes of the network) leading to adaptation. The long-term adaptation caused 
by steroids (in contrast to the short-term changes) include psychological symptoms 
(e.g., depression, fatigue) and somatic symptoms (bone fractures, skin thinning). All 
therapies carry some risk of adverse side effects because they affect mechanisms in 
addition to the target pathway, and it is the effect on these other mechanisms that 
could dysregulate the functioning of a biological network. However, because 
biologics have such a specific effect on the asthma inflammatory pathway, it is 
possible that these therapies can have a unique effect of reducing pathology in the 
network. Because of the substantial benefit reported by super-responders, which is 
difficult to explain in terms of improved respiratory function, this leads to a second 
prediction 
Super-responders to biologic treatment experience benefit because there is a 
reduction in the distributed pathology of the network, i.e., reduced network 
dysregulation. 
There is some evidence that biologic treatment reduces depression in patients with 
psoriasis [21, 22], which is consistent with the hypothesis that biologics have this 
additional benefit. The role of the immune system in depression is well established 
[23], so it is plausible that anti-inflammatory therapy for the lung reduces depression, 
but depression is also a correlate of other somatic and psychological symptoms 
whose etiology is linked to the immune system. 
Networks are complex systems of massive simultaneous causal connections. 
Depending on the initial state and depending on its inputs, networks can resolve into 
a particular stable state. The state of a network is determined by its historical state 
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such that different states, or local minima, are possible [24]. Change from one local 
minimum to another (for example, a lower local minimum) will involve the network 
moving initially in the opposite direction (see Figure 2). Let us suppose that 
networks vary in their level of dysregulation (high dysregulation = poor health, low 
dysregulation = good health), and that level of dysregulation can be assessed by the 
number of non-respiratory symptoms. Let us suppose further that the network can 
adapt as a function of its inputs, therapeutic or pathogenic, so that dysregulation 
either increases or decreases. If the network is currently in one local minimum, then 
therapeutic change that leads the network to resolve into another, less pathogenic 
local minimum will require the network to move initially in a more pathogenic 
direction. So, if therapy requires the network to change from one stable state to 
another less dysregulated state, then there should be an initial increase in non- 
respiratory symptoms before those symptoms reduce below the original level. 
Network adaptation is slow, so the increase and subsequent decrease in non- 
respiratory symptoms before their reduction could take a day or more. This leads to 
the following prediction 
Responders to biologic treatment (possibly only super-responders) may 
experience an increase in one or more non-respiratory symptoms for a period 
of time after starting (or receiving) biologic treatment, leading later to a 
reduction in those symptoms. Note: this prediction requires the network to 
resolves into local minima, and this is not yet established. 
If the benefit experienced by super-responders is due to reduced dysregulation in a 
network of pathogenic mechanisms, this raises two possibilities, irrespective of the 
above prediction. First, the use of biologics earlier in the patient’s history might 
prevent deterioration of non-respiratory symptoms. Second, biologics could have 
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therapeutic benefit in other conditions, in particular for those patients with functional 
disorders who have raised levels of the target molecule. Although the number of 
patients so benefiting is likely to be small, a possible area for investigation is 
fibromyalgia as the non-respiratory symptoms of severe asthma have a similar 
profile to that of fibromyalgia [25]. The recommendation is: 
Other uses of biologics should be considered if biologics reduce non- 
respiratory symptoms in asthma. 
As the pathogenic state of the network is affected by lifestyle, with health promoting 
lifestyle leading to less network pathology [13, 26], then multi-component lifestyle 
change interventions (exercise, psychology nutrition) provided with a narrative that 
engages patients and produces adherence (such as body reprogramming [27]) could 
improve the effectiveness of biologics. The final prediction is: 
Lifestyle improvement prior to biologic therapy should enhance the 
effectiveness of biologic therapy for severe asthma. 
Summary 
 
The number or profile of non-respiratory symptoms may predict response to 
biologics. Biologics may reduce non-respiratory symptoms, thereby explaining the 
substantial benefit reported by super-responders. Additional applications would 
follow if biologics were shown to reduce non-respiratory symptoms in asthma. 
Investigation of potential network effects should include measurement of change of 
non-respiratory symptoms over time. As it is theoretically possible that lifestyle 
interacts with biologics, lifestyle improvement prior to biologic therapy may improve 
response. 
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